Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Sees Large Drop in Short Interest

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) saw a large drop in short interest in February. As of February 13th, there was short interest totaling 73,194 shares, a drop of 88.2% from the January 29th total of 619,061 shares. Based on an average daily volume of 194,119 shares, the short-interest ratio is presently 0.4 days. Currently, 5.2% of the company’s stock are sold short. Currently, 5.2% of the company’s stock are sold short. Based on an average daily volume of 194,119 shares, the short-interest ratio is presently 0.4 days.

Shuttle Pharmaceuticals Trading Up 0.9%

Shares of NASDAQ:SHPH opened at $1.09 on Friday. The stock has a market cap of $1.74 million, a PE ratio of -0.09 and a beta of -1.02. The stock’s fifty day simple moving average is $1.65 and its two-hundred day simple moving average is $2.55. Shuttle Pharmaceuticals has a 1-year low of $1.00 and a 1-year high of $15.59.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC purchased a new stake in Shuttle Pharmaceuticals in the 4th quarter valued at about $26,000. Connective Capital Management LLC purchased a new position in shares of Shuttle Pharmaceuticals in the 3rd quarter worth approximately $357,000. Ikarian Capital LLC purchased a new position in shares of Shuttle Pharmaceuticals in the 4th quarter worth approximately $124,000. Finally, Boothbay Fund Management LLC bought a new position in shares of Shuttle Pharmaceuticals in the fourth quarter valued at approximately $37,000. 4.58% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

SHPH has been the topic of several research reports. Wall Street Zen upgraded shares of Shuttle Pharmaceuticals to a “sell” rating in a report on Saturday, November 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Shuttle Pharmaceuticals in a research report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .